Precision Therapeutics, Inc. Release: Data Demonstrating The Ability Of Chemofx® To Identify Platinum-Resistant Primary Ovarian Cancer Patients Prior To Treatment Published ByThe American Journal Of Obstetrics And Gynecology
2/24/2014 8:23:29 AM
PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics, a life-science company dedicated to improving patient outcomes in gynecologic cancer, today announced that a study evaluating the ability of the ChemoFx® chemoresponse assay to identify resistance to first-line treatment in ovarian cancer has been accepted for publication by the American Journal of Obstetrics and Gynecology (AJOG).
Help employers find you! Check out all the jobs and post your resume.
comments powered by